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Mortality and causes of death of end-stage renal disease in treatment for children with end-stage renal disease
children: A Dutch cohort study. (ESRD). Improvement in dialysis techniques and sup-
Background. To establish mortality rates, causes of death, portive therapies over the last two decades has placedand determinants of mortality in children with end-stage renal
chronic RRT in most children beyond controversy. Nota-disease (ESRD), we performed a national long-term follow up
study. bly, the introduction of bicarbonate buffer replacing
Methods. Mortality rate was determined in all Dutch pa- acetate in hemodialysis, continuous cycling peritoneal
tients with onset of ESRD at ages 0 to 14 years in the period dialysis (CCPD), and the use of recombinant human
between 1972 and 1992. Causes of death and mortality determi-
erythropoietin (EPO) and growth hormone (GH) ther-nants were investigated in all patients of this cohort who were
apy have been associated with a decrease in acute mor-born before 1979. Data were derived from the Dutch Registry
for patients on renal replacement therapy (RRT), medical bidity and mortality. Although treatment of infants is
charts and National Health Database. still being debated, recent studies advocate the initiation
Results. Of all 381 patients 85 had died. The overall mortality
of RRT even in this group [1].rate (MR) was 1.57/100 patient-years, and the standardized
Nevertheless, detailed information about the long-mortality rate (SMR) was 31.0. The MR for patients 0 to 5
and 6 to 10 years old at onset of ESRD decreased from, respec- term outcomes of RRT in children is lacking. Previous
tively, 7.0 (range 0–14.9) to 3.9 (1.2–6.7) and 4.3 (1.1–7.5) to studies on morbidity and mortality in these children have
1.6 (0.3–2.8) between the periods 1972–1981 and 1982–1992. relatively short follow-up times, show only crude andThe mortality hazard ratio of relatively long standing dialysis
incomplete registry data, or describe isolated groups ofand of long standing hypertension were, respectively, 7.2 (4.4–
11.8) and 3.1 (2.1–4.6), of cyclosporine-introduction in trans- transplanted children or children on dialysis [2–9]. There-
planted patients 0.3 (0.1–0.4). Overall cerebrovascular acci- fore, we conducted a national retrospective and prospec-
dents (24%) and infections (21%) were the most common tive cross-sectional study to evaluate the Late physical,
causes of death; after 10 years of RRT cardiac death (7/21)
social and psychological Effects of Renal InsuffiCiencywas most prevalent. Cardiovascular death was most prominent
(LERIC) in all Dutch children who started RRT be-in dialysis as well as transplanted patients.
Conclusion. Survival in children with ESRD has increased tween 1972 and 1992. This article reports the mortality
over the last 20 years, but the SMR remains high. Early trans- and causes of death.
plantation and a more vigorous approach toward hypertension
and infection may be mandatory in order to further reduce
mortality. METHODS
Participants: The total cohort and the LERIC cohort
Since the early seventies of the last century, renal The LERIC study was designed to examine the physi-
replacement therapy (RRT) has become an established cal, social and psychological consequences of pediatric
ESRD patients who were at an adult age. In 1972 the first
Dutch center for pediatric dialysis was officially opened.Key words: pediatric nephrology, renal replacement therapy, kidney
disease, LERIC study, dialyzed children. Before this year only a few children had been treated
with chronic dialysis and detailed information about
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order to have at least a (potential) follow-up period of vember 1, 1998 and the August 1, 2000. In living patients
the day of review was considered the day of the end ofsix years. We focused on the effects of childhood ESRD
when these patients had reached adulthood. Therefore, the study for that particular patient. We attempted to
localize all emigrated patients, and requested medicala cohort of patients was formed who had reached, or in
the event they had died, should have reached, adulthood information from their current physician.
Categorization of causes of death. Four classificationas defined as aged older than 18 years at the time of the
study. The LERIC cohort comprised all Dutch patients systems were use to define causes of death into catego-
ries: the American Health Care Financing Administra-who had started chronic RRT between 1972 and 1992
at age less than 15 years, and who were born before tion and the European Dialysis and Transplantation lists,
a list used by Tozawa et al, and our own LERIC classifi-1979. Patients in whom renal function recovered within
four months after commencing dialysis were excluded. cation system [4, 10, 11]. Causes of death were catego-
rized independently by three reviewers (J.W.G., M.P.G.,Preemptive transplanted patients were included. Data
on gender, date of birth, initiation of RRT, and date of and M.O.). After assessment of interobserver variability
for each classification system, the results were compareddeath of all the patients who fulfilled the inclusion crite-
ria were provided by the National Dutch Registry of and consensus was achieved. For this latter purpose, we
used the guidelines of the International Classification ofpatients on RRT (RENINE, Rotterdam, The Nether-
lands). RENINE, founded in 1985, is the Dutch source of Diseases of the World Health Organization [12].
Peritonitis without preceding intestinal pathology is athe European Dialysis and Transplantation Association.
The completeness approaches 100% as registration is complication that in ESRD patients almost exclusively
appears in patients on peritoneal dialysis. There is enoughcompulsory for reimbursement of RRT.
To estimate the unbiased mortality rates for all age evidence that the open connection to the peritoneal cav-
ity is the most important factor leading to peritonitis.groups, we enlarged the LERIC cohort with those pa-
tients who were excluded from the LERIC-study because Therefore, death by peritonitis was categorized as a
“complication of treatment” and not as an “infection.”they were to young, that is, those born after 1979. The
list of these patients was also provided by RENINE. Determinants of mortality. Data were collected on the
total duration of hemodialysis, peritoneal dialysis andThis extended cohort, termed as “the total cohort,” con-
sequently consisted of all Dutch patients who had started transplantation, primary renal disease, year and age at
initiation of first RRT, age at death, modality of RRTRRT between 1972 and 1992 at ages 0 to 14 years.
When the RENINE data on the LERIC-cohort were at time of death, the burden of hypertension and the use
of EPO and immunosuppressive therapy. The observa-compared with the data from all of the medical centers,
it turned out that the RENINE data on date of birth, tion period for all variable determinants lasted from the
first day of RRT until the day of chart-review. The totalstart of RRT and death were very accurate, but that
information about cause of death was lacking. For this duration of RRT, hemodialysis, peritoneal dialysis and
transplantation was expressed in days. Hypertension wasreason the total cohort data were used only to describe
mortality while the LERIC cohort data were used to scored as follows: the mean blood pressure per three
months was calculated from all documented blood pres-describe cause of death and the relationships between
mortality rates and determinants. sure values and recorded on file. In hemodialysis patients
the mean of pre- and post-dialysis blood pressure wasThe health statistics of the Health and Welfare Depart-
ment of Statistics Netherlands (Centraal Bureau voor used to calculate the three-month period mean. Over
periods of uneventful follow-up after transplantation inStatistiek, Voorburg, The Netherlands) were used to cal-
culate standardized mortality rates. which patients were controlled less frequently than once
per three months, the mean value of two subsequently
Data collection recorded blood pressure values was presumed to repre-
sent the mean blood pressure of the three-month periodLogistics. Patients who started RRT before 1985 are
registered retrospectively in the RENINE database. The lying in between these measured blood pressures. All
eventful periods since onset of RRT over which dataaccuracy of data on these patients was checked by com-
paring RENINE data with the databases of all four could not be obtained were excluded from evaluation
and recorded as missing patient-years. Hypertension wasDutch centers for pediatric dialysis and kidney trans-
plantation, and with the databases of all centers for adult defined as both systolic and diastolic blood pressure
above the 95th percentile for age, in accordance withdialysis and transplantation.
Members of the LERIC team (J.W.G., M.P.G., J.H., the Task Force on Blood Pressure in Children [13]. The
total number of periods of hypertension and normalH.C., B.D., J.vdM., A.vdG.) visited 37 hospitals in the
Netherlands in order to collect all available information blood pressure were recorded.
Since follow-up time varied between individual pa-on the cause of death in all LERIC patients. To achieve
this goal, all medical charts were reviewed between No- tients, the effects of hypertension and dialysis on out-
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come were analyzed as follows. For each patient a ratio sus transplantation, and of hypertension and supportive
therapy during the observation period. Dialysis as a riskof total number of blood pressures with values above
the 95th percentile divided by the total number of blood factor compared to transplantation was analyzed in two
ways: firstly as the RRT mode at the end of the studypressures with values below the 95th percentile, was cal-
culated. Patients with a ratio of more than one were period (that is, at the time of death or in August 2000)
and secondly by comparing total duration of dialysiscategorized as patients with a “relatively long standing”
hypertension. Thus, a patient with “a relatively long versus transplantation in both groups of surviving and
deceased patients. Hemodialysis and peritoneal dialysisstanding” hypertension had a more days of RRT with a
blood pressure above the 95th percentile than days with were analyzed separately by comparing total peritoneal
dialysis- and hemodialysis-time in surviving and de-a blood pressure below the 95th percentile. The mean
mortality rates of these patients were compared with ceased patients. Continuous variables were transformed
into dichotomous variables for the calculation of inci-those with a ratio of less than one. The same technique
was used for analysis of the relationship with mortality of dence rate ratios: patients with a total dialysis duration
that exceeded the total time with a functioning graftdialysis versus transplantation and hemodialysis versus
peritoneal dialysis. Thus, patients with a “relatively long were compared with those with the inverse situation.
The same approach was used for hemodialysis versusstanding” period of dialysis were considered those who
had more days of RRT on dialysis than days living with transplantation, peritoneal dialysis versus transplanta-
tion, hemodialysis versus peritoneal dialysis and hyper-a functioning renal graft. In the same way we defined
“a relatively long standing period” of hemodialysis by tension versus normal blood pressure. The effect of the
introduction of cyclosporine, ATG and OKT3 as newthe ratio of total hemodialysis time over total peritoneal
dialysis of more than one. immunosuppressive therapy was analyzed in all patients
who were ever transplanted in patients with RRT asThe medical ethics committees of all participating cen-
ters approved the study design. last RRT, and in patients with at least five years of
transplantation as RRT.
Statistical analysis The SPSS 9.0 program was used for all statistical calcu-
lations (SPSS Inc., Chicago, IL, USA).The mortality rate (MR) was expressed as the number
of deaths per 100 patient years on renal replacement
therapy. The standardized mortality rate (SMR) was de-
RESULTS
fined as the MR for a certain age group in a certain year
Total cohort and LERIC cohortdivided by the expected mortality for the same age group
and year. MR was calculated separately for different age The total cohort consisted of 381 patients.
Formation of the LERIC cohort revealed that fromgroups during two different periods of initiation of RRT,
before and after 1982. the RENINE database, 251 patients matched the inclu-
sion criteria. Verification using the local databases of allWe used Kaplan-Meier analysis to calculate survival
probabilities. the participating centers revealed that one patient was
mentioned twice, and three patients did not match theThe effect of change in dialysis techniques, transplant
protocols and supportive therapy over time on causes of inclusion criteria. Reviewing the databases of all dialysis
and transplantation centers elicited two additional pa-death was analyzed by comparing the death rates of
patients who started renal replacement therapy between tients. Therefore, the definite LERIC cohort consisted
of 249 subjects. According to the RENINE registration1982 and 1991 and of those who started RRT between
1972 and 1981. seven patients had been lost to follow-up. On our verifi-
cation, six of these patients were still alive and one pa-The associations of gender, age at initiation of renal
replacement therapy, and the time period of initiation tient had died. Also, initially it appeared that in 43 of
63 deceased patients the cause of death was “unknown,”of RRT with outcome were analyzed in the total cohort
as well as the LERIC cohort. All other determinants but we were able to establish all causes of death except
one.were analyzed in the LERIC cohort.
The Cox proportional-hazards model was used to esti- For all of the LERIC patients we recorded a total of
3870 patient-years, covering the entire period from themate the relative mortality risk for several determinants.
These determinants had been established at the begin- onset of renal RRT until August 2000 or time of death,
with 81 patient years missing and with an average follow-ning of the observation period and included gender, age
at initiation of RRT, period of RRT onset (1972–1982 up of 15.5 years per patient. Of all 249 patients 231 were
transplanted at least once.vs. 1982–1992), and primary disease. We calculated mor-
tality incidence rate ratios for determinants whose status The mean total RRT, transplantation, hemodialysis,
and peritoneal dialysis time were 16.0 years (range 0.3–could only be established at the end of follow-up. These
latter determinants include total duration of dialysis ver- 31.1), 11.7 years (range 0–29.9 years), 3.3 years (range
Groothoff et al: Juvenile CRF mortality and causes of death624
Table 1. Characteristics of the total cohort and the LERIC cohort
Total cohort LERIC cohort
Number of patients 381 249
Male/female 216/165 136/113
Number of deaths 85 (22.3%) 63 (25.3%)
Number of deaths/total numbers starting RRT before 1/1/82 45/151 45/151
Number of deaths/total numbers starting RRT after 1/1/82 40/230 18/98
Mean age start RRT, years (range) 8.6 (0.5–14.9) 10.6 (1.9–14.9)
Mean age of death, years (range) 17.3 (0.1–36.4) 17.5 (4.2–36.4)
Mean time between first RRT & death, years (range) 6.5 (0.1–25.9) 7.3 (0.3–25.9)
Median time between first RRT & death, years (range) 3.7 (0.1–25.9) 4.3 (0.3–25.9)
Died while on peritoneal dialysis No data 7 (11.1%)
Died while on hemodialysis No data 31 (49.2%)
Died with a functioning renal graft No data 25 (39.7%)
Abbreviation is RRT, renal replacement therapy.
Table 2. Mortality rates (MR) per 100 patient years and standardized mortality rates (SMR)
(with 95% confidence interval) in the total cohort
MR age
Time period MR cohort SMR cohort 0–5 yearsa 6–10 yearsa 11–15 yearsa 16–20 yearsa
1972–1999 1.5 (1.2–1.9) 31.0 (24.7–38.3) 3.5 (1.5–5.5) 2.1 (1.1–3.1) 1.8 (1.1–2.5) 1.3 (0.6–1.9)
1972–1981 3.6 (2.2–5.0) 72.4 (46–109) 7.0 (0–14.9) 4.3 (1.1–7.5) 2.1 (0.9–3.3) 1.4 (0–3.3)
1982–1991 1.6 (1.1–2.1) 29.4 (20.6–40.7) 3.9 (1.2–6.7) 1.6 (0.3–2.8) 2.0 (0.8–3.1) 1.3 (0.3–2.2)
1992–1999 1.2 (0.7–1.6) 21.0 (13.7–30.7) 1.0 (0–3.0) 1.5 (0–2.9) 0.8 (0–1.8) 1.3 (0.3–2.3)
Standardized mortality rate (SMR) is the observed age-specific mortality rate divided by the expected mortality rate in the general Dutch population.
a Age at onset of renal replacement therapy
0–25.6), and 0.8 years (range 0–14.7 years), respectively. patients who died with a functioning renal graft, 4 (16%)
died within 31 days and 6 (24%) with four months afterTransplantation had been performed twice in 118 pa-
tients, three times in 38 patients, and four times in 8 transplantation.
patients. Patients changed from therapy-modality (that
Mortality risk factors and causes of deathis, dialysis or functioning graft) between one to nine
times during the study period. Of the 249 subjects only The risk ratios with respect to overall mortality of
a relatively long period of dialysis and relatively longtwo never had been treated with dialysis, while 18 pa-
tients never had been transplanted. standing hypertension were 7.2 (95% CI, 4.4–11.8) and
3.1 (95% CI, 2.1–4.6), respectively. In patients with atMain characteristics of both total cohort and LERIC
cohort are given in Table 1. least one transplantation episode, the use of cyclosporine
was associated with a mortality risk of 0.3 (95% CI,
Mortality 0.1–0.4). Cumulative incidence ratios and Cox regression
hazard ratios of these and other mortality risk factorsOf the 381 patients comprising the total cohort, 85
had died. The total follow-up period was 7 to 28 years. are presented in Table 3.
Table 4 shows the cause-specific death rates amongThe overall Mortality Rate was 1.57 per 100 patient-
years. The mean SMR was 31 for the entire period and all subjects. The data of one patient who died in 1974
were unrecoverable. Official cause of death in two pa-39.2 for the period 1972–1992; it decreased from 72.4
between 1972 and 1981 to 29.4 between 1982 and 1992 tients was “cardiac arrest.” One of them, who underwent
an otherwise uncomplicated chronic hemodialysis treat-(Table 2). The SMR and age-group specific MR for three
time periods are summarized in Table 2. Overall, five-, ment, died suddenly at home after a short moment of
acute chest pain and shortness of breath. The other pa-ten- and twenty-year survival rates after RRT onset were
87, 82 and 78%, respectively. Five- and ten-year survival tient died of acute asystole during a hemodialysis ses-
sion. No heart-threatening electrolyte disturbances wererates increased from 81% and 79% in the 1972–1981
period, respectively, to 89% and 85% in the 1982–1991 found and an autopsy of the patient revealed no evidence
for embolism or cerebrovascular bleeding. Therefore,period (Fig. 1).
Of the 249 patients comprising the LERIC cohort, the conclusion was that an acute arrhythmia (in one
established), secondary to left ventricular hypertrophy,63 had died, 25 with a functioning graft, 31 while on
hemodialysis, and 7 on peritoneal dialysis. Of the 25 would have been responsible for the death of these pa-
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Fig. 1. Kaplan-Meier survival rates of two
subgroups of all patients of the RENINE-
cohort, starting renal replacement therapy, re-
spectively, between 1972-1981 (solid line) and
1982-1991 (dashed line).
tients. For this reason we categorized these patients as compared to 4.4% in the group of patients with a rela-
tively short period of hypertension (RR 2.5; 95% CI“cardiovascular deaths.”
Cardiovascular diseases, infections, cessation of treat- 1.0–6.7). Of the patients with a relatively long period of
dialysis, 17.8% died of cerebrovascular accidents com-ment, malignancies and complication of treatment ac-
counted for 41%, 21%, 11%, 10% and 8% of all deaths, pared to 1.1% (RR 15.7; 95% CI 3.6–67.7) of those with
a relatively short period of dialysis.respectively. Of all 15 patients who died of a cerebrovas-
cular accident, 11 (73.3%) were treated with hemodialy- There was a decline in the relative number of deaths by
cardiovascular disease and by complication of treatmentsis, one (6.7%) with peritoneal dialysis, and three (20%)
had a functioning renal graft at time of death. Of the six over time. The risk of cardiovascular death among the
group who commenced RRT after 1981 was 0.4 (rangepatients with a renal graft who died within four months
after transplantation, five died of infection and one of 0.2–1), relative to the group who commenced treatment
between 1972 and 1981. Twenty out of 144 RRT patientsintestinal hemorrhage.
Within the first ten years of RRT 42 patients who were (13.4%), who started between 1972 and 1981, died of
cardiovascular disease, compared to 6 out of 100 patients,followed for 2177.7 years at risk ( 1.93/100 patients-
years) died, compared to 21 patients in the period after who started RRT after 1981. No differences were found
in mean age at the start of RRT or median time on RRTten years of RRT who were followed for 1660.76 years (
1.26/100 patient-years). In the former group cerebrovas- between both groups. No deaths due to complication of
treatment or “other causes” were seen in the group whocular accidents and infection (both 11/42  26%) were
the most prominent causes of death. In patients who commenced RRT after 1981 (Table 5).
In 38 patients who died while undergoing chronic dial-died after ten years of RRT, cardiac death (7 of 21 
33%) was most common. ysis treatment, death was caused by cardiovascular dis-
ease in 45%, and by infection, cessation of treatment, andOf the total patients with a relatively long period of
hypertension, 11.1% died of cerebrovascular disease complication of treatment each in 13%. Cardiovascular
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Table 3. Risk factors with respect to overall mortality in the total cohort and the LERIC cohort
Group Aa Group Bb
Cohort Deaths/N RR 95% CI
Total cohort (N381)
Male (A) vs. female (B) 47/216 36/165 1.1c 0.7–1.6
Start RRTf 1972–1981 (A) vs. 1982–1991 (B) 47/152 38/229 1.7c 1.0–2.7e
Age start RRT 6 years (A) vs. age start RRT 5 years (B) 30/106 55/275 2.2c 1.3–3.5e
LERIC cohort (N249)
Male (A) vs. female (B) 34/136 29/113 1.0c 0.6–1.5
Start RRT 1972–1981 (A) vs. 1982–1991 (B) 45/149 18/100 1.3c 0.8–2.1
Age start RRT 6 years (A) vs. age start RRT 5 years (B) 12/19 51/230 3.4c 1.8–6.4e
Dialysis as last mode of RRT (A) vs. Tx (B)g 38/78 25/171 3.3d 2.1–5.1e
Primary disease with other vital organs affected (A)h 9/19 54/230 2.4c 1.1–5.1e
Duration dialysis (A) vs. duration Tx (B)i 47/73 16/176 7.2d 4.4–11.8e
Duration hemodialysis (A) vs. duration Tx (B)j 41/61 22/188 5.7d 3.7–8.8e
Duration hemodialysis (A) vs. peritoneal dialysis (B)k 57/186 6/63 2.1d 1.0–4.4e
Relatively long period of hypertension (A)l 25/63 31/177 3.1d 2.1–4.6e
Use (A) vs. no use (B) of EPOm: all patients 12/99 51/150 0.4d 0.2–0.6e
Use (A) vs. no use (B) of EPO: patients starting RRT ’81 (N99) 7/50 11/49 0.6d 0.2–1.5
Use (A) vs. no use (B) of CsAn: all Tx patientso 14/147 32/84 0.3d 0.1–0.4e
Use (A) vs. no use (B) of CsA: Tx patients starting RRT ’81p 7/79 6/15 0.2d 0.1–0.5e
Use (A) vs. no use (B) of CsA: patients with Tx as last RRTq 6/107 19/64 0.2d 0.1–0.4e
Use (A) vs. no use (B) of CsA: patients with Tx-duration 5 yearsr 7/130 10/59 0.3d 0.1–0.8e
Use (A) vs. no use (B) of high-dose steroids: all Tx patients 27/157 21/74 0.6d 0.4–1.0
Use (A) vs. no use (B) of high-dose steroids: patients with Tx 5 years 10/130 7/59 0.7d 0.3–1.6
Use (A) vs. no use (B) of ATG/OKT3: all Tx patients 13/87 33/144 0.6d 0.4–1.2
Use (A) vs. no use (B) of ATG/OKT3: patients with Tx 5 years 6/73 11/116 0.9d 0.3–2.2
a Number of deaths divided by total number of all patients with investigated risk factor (group A)
b Number of deaths divided by total number of all patients without risk factor (group B)
c Cox regression analysis
d Cumulative incidence ratio
e P  0.05
f RRT, renal replacement therapy
g Tx, transplantation
h Patients with SLE, Goodpasture, oxalosis, cystinosis or autosomal recessive cystic disease (A) vs. patients with an other primary disease (B)
i Patients with a total dialysis/total transplantation duration ratio 1 (A) vs. patients with a ratio 1 (B)
j Patients with a total hemodialysis/transplantation duration ratio 1 (A) vs. patients with a ratio 1 (B)
k Patients with a total hemodialysis/total peritoneal dialysis duration ratio 1 (A) vs. patients with a ratio 1 (B)
l Patients with a total hypertension duration/normal blood pressure duration ratio 1 (A) vs. patients with a ratio 1 (B)
m EPO, Erythropoietin
n CsA, cyclosporine-A
o Patients with at least 1 transplantation period, ever used cyclosporine (A) vs. patients on azathioprine (B) (N  231)
p Patients with at least 1 transplantation period, ever used cyclosporine (A) vs. patients on azathioprine (B), starting RRT after 1/1/1982 (N  94)
q Patients with at least 1 transplantation period, ever used cyclosporine (A) vs. patients on azathioprine (B), with Tx as last RRT (N  171)
r Patients with at least 1 transplantation period, ever used cyclosporine (A) vs. patients on azathioprine (B) (N  189)
diseases (36%), infection (28%) and malignancies (20%) introduction of cyclosporine was associated with a sig-
nificant reduction in mortality rate in all transplantedwere the most common causes of death in patients who
patients. Cardiovascular diseases, especially cerebrovas-died with a functioning renal graft.
cular accidents, accounted for more than 40% of all
deaths, as well in dialysis patients and in transplanted
DISCUSSION patients. Improvement of treatment over time resulted
In this cohort study all Dutch patients with juvenile in a reduction of cardiovascular deaths and death caused
ESRD were followed for at least eight years. Overall by direct complications of treatment.
mortality in this group with chronic RRT was more than We used the RENINE data of the total cohort to
30 times higher than in age- and gender-matched Dutch calculate the mortality rate, since the accuracy of the
youngsters. Half of all the deceased patients died within RENINE data on the mortality of the LERIC data was
four years after initiation of RRT. Although overall sur- 97%. The observed overall mortality rate of 1.57 per 100
vival was higher in patients who started with RRT after patient years is somewhat lower than reported in the
1981, this accounted only for patients with onset of RRT mid nineties by Reiss et al [7] and by the American
under the age of ten. Onset of RRT at young age, a USRDS in children, which was 2.0 per 100 patient-years
relatively long dialysis period, systemic and metabolic in children on renal replacement therapy between 0 and
primary diseases, and a relatively long period of hyper- 19 years [2, 14]. This difference could be explained by
the longer follow-up period in the current study, sincetension were associated with an increased mortality. The
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Table 4. Causes of death
Age at onset RRT Age at time of death
Patients RRT at time
Cause of death (N) of death years
Cardiovascular 26
Cerebrovascular accident 15 HD 11, PD 1, Tx 3 3–12 5–26
Congestive heart failure 4 Tx 3, HD 1 2–14 7–31
Myocardial infarction 3 HD 2, Tx 1 12, 14, 14 24, 27, 36
Cardiac arrest 2 HD 1, Tx 1 10, 13 17, 28
Pericarditis 1 HD 1 6 6
Aorta dissection 1 Tx 1 12 25
Complication treatment 5
Peritonitis 3 PD 3 4, 10, 14 5, 18, 21
Sclerotic peritonitis 1 PD 1 9 27
Shunt bleeding 1 HD 1 8 34
Infection 13
Septicemia 7 HD 4, PD 1, Tx 2 3–14 4–21
Pneumocystis carinii 2 Tx 2 10, 12 12, 13
CMV 2 Tx 1, PD 1a 14, 10 20, 12
Fungal encephalitis 1 Tx 1 10 12
Dengue 1 Tx 1 13 33
Malignancies 6
Non-Hodgkin lymphoma 4 Tx 4 4–14 10–28
Leukemia 1 Tx 12 27
Fibrosarcoma 1 Tx 11 15
Refusal further treatment 7 HD 5, Tx 2 5–14 12–36
Other 6
Hyperkalemia 3 HD 3 5, 13, 14 6, 16, 16
Cachexia 1 PD 8 9
Abdominal bleeding 1 Tx 9 13
No data 1 HD 14 16
Abbreviations are: RRT, renal replacement therapy; HD, hemodialysis; PD, peritoneal dialysis; Tx, transplantation.
a 5 days on peritoneal dialysis after years of transplantation
Table 5. Mortality and causes of death in the LERIC cohort by calendar period of RRT initiation
N/pt-years N/pt-years RR RR (95% CI)
1972–1981 1982–1992 1972–1981 1982–1992
All causes 45/1558.1 18/1168.6 1 0.54 (0.3–0.9)a
Cardiovascular 20/1558.1 6/1168.6 1 0.4 (0.2–1.0)a
Infection 6/1558.1 7/1168.6 1 1.6 (0.5–4.6)
Complication treatment 5/1558.1 0/1168.6 1 0a
Malignancy 4/1558.1 2/1168.6 1 0.67 (0.1–3.6)
Stop treatment 3/1558.1 4/1168.6 1 1.78 (0.4–7.9)
Other 6/1558.1 0/1168.6 1 0a
Abbreviations are: RRT, renal replacement therapy; RR, relative mortality risk, related to the mortality rate in the period 1972–1981.
a P  0.05
the median of time between initiation of RRT and death ward an increase in cardiac deaths after ten years of
RRT. The fact that no reduction in lethal infections waswas only 3.7 years. The cumulative survival of 82% is
comparable with other reports [6, 9, 15, 16]. To our seen over time is compatible with other recent reports
[2, 3, 7], and is a continuing concern for the future.knowledge, until now no data on standardized morality
rates in patients with juvenile end-stage renal disease A relatively long duration of hypertension was associ-
ated with a threefold death rate. The percentage ofhave been reported.
The observed 24% cumulative incidence of lethal cerebrovascular deaths was more than twice as high in
the hypertension-group, compared to patients with a rel-cerebrovascular accidents in the LERIC cohort was
much higher than that reported by the USRDS (6%) atively short period of hypertension. As far as we know,
there are no data on the impact of hypertension on sur-and Reiss et al (2%) [3, 8]. The discrepancy with the
American data could partly be explained by the high vival in children with ESRD. It seems obvious that hyper-
tension is a predictor of cardiac death in patients withpercentage of missing causes in the USRDS database [2,
3, 10]. As was to be expected from data from studies in ESRD, since it is well established that left ventricular
hypertrophy correlates with cardiac mortality, as well asadults with ESRD, in our study the balance tended to-
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with the severity of hypertension [17]. Nevertheless, most it would not influence the stabilization of the mortality
we found in the age group 11 to 15 years, nor would itstudies in adults show no or only a weak direct relation-
ship between malignant hypertension and mortality in change the persistent high SMR we found.
dialyzed patients [18–20]. Charra et al found that the We believe that this long-term study provides a com-
survival of dialyzed patients with a mean arterial pres- plete and rather accurate picture on mortality and causes
sure above 99 mm Hg was inferior to the survival of of death in children on renal replacement therapy. No
those with a mean arterial pressure below 99 mm Hg patients were lost to follow-up, and data about the cause
[21]. Yet other data from studies in adult hemodialysis of death were lacking for only one patient, who died in
patients suggest that abnormally high (180 mm Hg) as the early seventies.
well as abnormally low systolic blood pressures (110 In conclusion, although the survival in children with
mm Hg) are associated with decreased survival [11, 22]. end-stage renal disease has increased over the last 20
Low systolic blood pressures in older dialysis patients years, the standardized mortality rate remains high.
could reflect the poor ventricular function in advanced Early transplantation and a more aggressive approach
cardiac disease and might therefore be related to cardiac toward hypertension and infection may be mandatory
mortality, whereas in younger patients the impact of in order to reduce mortality.
hypertension on fluid overload and ventricular hypertro-
phy might prevail [17, 23]. Our data are consistent with ACKNOWLEDGMENTS
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